Femoral Stress Fractures Associated With Long-term Bisphosphonate Treatment

BackgroundRecent studies have described unique clinical and radiographic characteristics of femoral stress fractures or low-energy fractures associated with long-term bisphosphonate therapy. However, it is unclear whether these fractures require subsequent surgery after the initial treatment.Questions/purposesWe performed a cohort analysis of bisphosphonate-associated femoral stress fractures to (1) confirm the unique clinical and radiographic findings compared with existing literature, (2) determine whether any patients with completed fractures had no preexisting transverse stress fracture lines, (3) assess the need for additional surgical procedures, and (4) determine whether the hospital length of stay (LOS) differed for patients with prophylactic fixation of stress fractures versus fixation of completed fractures.MethodsWe retrospectively reviewed 16 patients with 24 diaphyseal and subtrochanteric femoral stress fractures (14) or low-energy fractures (10) who had been on bisphosphonates for 3 to 10 years. Data included demographics, symptoms, medication history, radiographic characteristics, treatment parameters, LOS, and outcome. Minimum followup was 9 months (average, 44.0 months; median, 31 months; range, 9–112 months).ResultsAll patients had clinical and radiographic findings similar to those reported in the literature. Two of four patients sustained completed fractures after radiographs failed to reveal transverse lateral fracture lines. None of the 14 prophylactically treated impending fractures progressed or required additional surgery; however, in five of 10 femurs treated after fracture completion, six additional surgeries were performed. The average hospital LOS was shorter in patients who underwent prophylactic fixation (3.8 days) than in patients treated for completed fractures (5.6 days).ConclusionsBisphosphonate-associated stress fractures and completed fractures are unique, possessing subtle characteristic radiographic features. Completed fractures may occur through the thickened bone in the absence of an appreciable transverse stress fracture line. Our observations suggest prophylactic reconstruction nail fixation may avoid fracture completion and may be associated with a shorter hospital LOS and less morbidity than treatment of completed fractures.Level of Evidence Level IV, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.

[1]  N. Tejwani,et al.  Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. , 2009, The Journal of bone and joint surgery. American volume.

[2]  M. Goddard,et al.  Atraumatic bilateral femur fracture in long-term bisphosphonate use. , 2009, Orthopedics.

[3]  Thomas D Brown,et al.  Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  M. Vrahas,et al.  Nonoperative versus Prophylactic Treatment of Bisphosphonate-associated Femoral Stress Fractures , 2011, Clinical orthopaedics and related research.

[5]  S. Cummings,et al.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. , 2006, JAMA.

[6]  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. , 2007, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[7]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[8]  E. Barrett-Connor,et al.  Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  S. Ott Long-term safety of bisphosphonates. , 2005, The Journal of clinical endocrinology and metabolism.

[11]  T. Howe,et al.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? , 2008, Injury.

[12]  L. Assael,et al.  American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. , 2009, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[13]  J. Nieves,et al.  Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates , 2010, Current osteoporosis reports.

[14]  T. Howe,et al.  Femoral Cortical Stress Lesions in Long-Term Bisphosphonate Therapy: A Herald of Impending Fracture? , 2010, Journal of orthopaedic trauma.

[15]  W. Ward,et al.  Metastatic Disease of the Femur: Surgical Treatment , 2003, Clinical orthopaedics and related research.

[16]  J. Zerwekh,et al.  Severely suppressed bone turnover: a potential complication of alendronate therapy. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  J. Schneider Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. , 2009, Geriatrics.

[18]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[19]  A. Sayed-Noor,et al.  Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy , 2009, Clinical orthopaedics and related research.

[20]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[21]  M. Gebhart,et al.  Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy , 2010, Clinical orthopaedics and related research.